Philadelphia Financial Management of San Francisco LLC purchased a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,343,007 shares of the company's stock, valued at approximately $8,353,504,000. ASP Isotopes accounts for approximately 1.7% of Philadelphia Financial Management of San Francisco LLC's investment portfolio, making the stock its 19th largest position. Philadelphia Financial Management of San Francisco LLC owned 0.88% of ASP Isotopes as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. HITE Hedge Asset Management LLC bought a new position in ASP Isotopes in the fourth quarter valued at about $2,407,000. Encompass Capital Advisors LLC purchased a new stake in ASP Isotopes in the 1st quarter valued at about $30,551,000. SBI Securities Co. Ltd. raised its holdings in shares of ASP Isotopes by 196.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 152,120 shares of the company's stock worth $814,000 after purchasing an additional 100,769 shares during the period. AWM Investment Company Inc. bought a new stake in shares of ASP Isotopes during the 2nd quarter valued at $9,837,000. Finally, WIM INVESTMENT MANAGEMENT Ltd bought a new position in ASP Isotopes in the 4th quarter worth about $3,217,000. Institutional investors and hedge funds own 16.80% of the company's stock.
Insider Activity at ASP Isotopes
In other ASP Isotopes news, Director Todd Wider sold 50,000 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $6.25, for a total value of $312,500.00. Following the completion of the sale, the director owned 722,247 shares of the company's stock, valued at $4,514,043.75. The trade was a 6.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael Gorley sold 30,000 shares of the company's stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the transaction, the director directly owned 87,908 shares of the company's stock, valued at approximately $551,183.16. The trade was a 25.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 279,079 shares of company stock worth $2,049,208 in the last quarter. 14.40% of the stock is owned by corporate insiders.
ASP Isotopes Stock Performance
NASDAQ:ASPI opened at $3.94 on Thursday. The firm's 50 day moving average is $4.78 and its two-hundred day moving average is $5.27. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. The company has a market cap of $604.04 million, a P/E ratio of -2.98 and a beta of 3.61. ASP Isotopes Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $14.49.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The business had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.
Analyst Upgrades and Downgrades
ASPI has been the subject of a number of analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Wall Street Zen upgraded ASP Isotopes from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $13.00.
Check Out Our Latest Analysis on ASP Isotopes
ASP Isotopes Profile
(
Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
